Nivolumab who discovered?

Who discovered nivolumab?

Nivolumab was developed by Bristol Myers Squibb (BMS) as a monoclonal antibody immunotherapy [1]. It targets the PD-1 (programmed death-1) receptor and is used in several cancers.

Which scientists or institutions are credited?

The publicly available attribution is generally to the company that developed the drug program (Bristol Myers Squibb), rather than to a single individual “discoverer” in standard drug references [1]. If you want, I can narrow this down further to the specific research groups/author teams credited in the earliest scientific papers tied to the PD-1 antibody program—but that requires knowing which “discovered” meaning you mean (e.g., discovery of PD-1 biology vs. discovery/development of the specific antibody drug).

How does this differ from discovery of PD-1?

PD-1 biology (the immune checkpoint pathway) is a separate scientific advance from the creation of nivolumab itself. Nivolumab is the drug product that was engineered and developed to block PD-1, but the foundational PD-1 research involves different investigators and publications than the nivolumab development program [1].

Source

[1] https://www.drugs.com/monograph/nivolumab.html